IVIG for Drug and Device Refractory Gastrointestinal Auto-Immune Neuropathy

Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY

Patients with the symptoms of generalized GI dysmotility, including gastroparesis, are sometimes refractory to available medications, devices and other interventions/ Some of these patients have serologic and/or endo organ abnormalities and findings consistent with autoimmune neuropathies, primarily involving the GI tract. These disorders have been known as autoimmune gastrointestinal neuropathies (GAIN) or also as autoimmune gastrointestinal dysmotility (AGID), among other terms. Some patients respond to intravenous immunoglobulin (IVIG) and this study, which is an observational clinical series, documents the patients, their findings and standardized responses to therapy with IVIG.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 12
Maximum Age: 90
Healthy Volunteers: f
View:

• \-

Locations
United States
Kentucky
University of Louisville
RECRUITING
Louisville
Contact Information
Primary
Thomas L Abell, MD
thomas.abell@louisville.edu
(502)852-6991
Time Frame
Start Date: 2020-01-02
Estimated Completion Date: 2028-01-02
Participants
Target number of participants: 400
Related Therapeutic Areas
Sponsors
Leads: University of Louisville

This content was sourced from clinicaltrials.gov